3SBio Inc. (TRSBF)

OTCMKTS · Delayed Price · Currency is USD
4.250
-0.490 (-10.34%)
Jul 30, 2025, 10:13 AM EDT
-10.34%
Market Cap9.59B
Revenue (ttm)1.25B
Net Income (ttm)286.38M
Shares Outn/a
EPS (ttm)0.12
PE Ratio33.50
Forward PE28.90
Dividendn/a
Ex-Dividend Daten/a
Volume162
Average Volume1,810
Open4.250
Previous Close4.740
Day's Range4.250 - 4.250
52-Week Range0.723 - 4.740
Beta0.79
RSI84.63
Earnings DateAug 22, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5,577
Stock Exchange OTCMKTS
Ticker Symbol TRSBF
Full Company Profile

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY Financial Statements

News

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm’s cancer drug, marking the largest deal ever for a sing...

5 days ago - South China Morning Post

Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma

The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega deal for righ...

2 months ago - Benzinga

Pfizer Thinks Bigger With 3SBio Deal

2 months ago - Seeking Alpha

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

2 months ago - Investopedia

Pfizer strikes deal with China's 3SBio to license cancer drug

CNBC's Angelica Peebles joins 'Squawk Box' to report on the latest news.

2 months ago - CNBC

Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal

Pfizer Inc. (NYSE: PFE) announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc. ‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion. The agree...

2 months ago - Benzinga